Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex's CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). In the United States, Trikafta sales are being fueled by label expansions to younger age groups (two to five years old). In the ex-U.S. markets, the drug continues to witness strong uptake with recently achieved reimbursements and expanded use in young age groups. The trend is expected to continue for the rest of the year. While CF remains the main area of focus, Vertex has seen rapid success in its non-CF pipeline candidates' development in the past year. Vertex and partner CRISPR Therapeutics ' CRSP one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), in multiple regions in 2023 and early 2024. These approvals have diversified its commercial opportunity. In the past year, the stock has risen 31.2% against the in
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis) [Seeking Alpha]Seeking Alpha
- Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought [Yahoo! Finance]Yahoo! Finance
- Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report? [Yahoo! Finance Canada]Yahoo! Finance Canada
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 6/3/24 - Form 8-K
- 5/31/24 - Form 4
- 5/31/24 - Form 4
- CRSP's page on the SEC website